Document Type: Original Research
Dept. of Cardiology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
Dept. of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
Background and Objectives: Lipoprotein-a potentially represents a useful tool for risk stratification in cardiovascular accidents. The aim of this study was to evaluate the atorvastatin effect on serum lipid profile & lipoprotein A.
Material & Methods: In 2009, 405 patients with acute coronary syndrome randomly were divided into 2 groups, taking 20 & 40 mg atorvastatin daily for 3 months. Lipid profile & lipoprotein-A serum levels were checked at the beginning of the study and also one and three months later.
Results: There was no statistical difference between the two groups in all measurements except in patients with unstable angina. The difference lay in the change of LP-a level after one month (P=0.045) and in apo-A level in all patients in the second and the third measurements compared with the first one (P=0.001 & P=0.002).
Discussion: It appears that the two doses (20mg and 40mg) of atorvastatin have a reduction effect on lipoprotein-A and serum lipid levels, but no difference is seen in the level of reduction. The 40 mg atorvastatin leaves more effects on reduction of apo-A than on the 20 mg after one and three months.